AR091908A1 - COMPLEJO CRISTALINO DE 1-CIANO-2-(4-CICLOPROPIL-BENCIL)-4-(b-D-GLUCOPIRANOS-1-IL)-BENCENO, METODOS PARA SU PREPARACION Y SU USO PARA PREPARAR MEDICAMENTOS - Google Patents

COMPLEJO CRISTALINO DE 1-CIANO-2-(4-CICLOPROPIL-BENCIL)-4-(b-D-GLUCOPIRANOS-1-IL)-BENCENO, METODOS PARA SU PREPARACION Y SU USO PARA PREPARAR MEDICAMENTOS

Info

Publication number
AR091908A1
AR091908A1 ARP130102660A ARP130102660A AR091908A1 AR 091908 A1 AR091908 A1 AR 091908A1 AR P130102660 A ARP130102660 A AR P130102660A AR P130102660 A ARP130102660 A AR P130102660A AR 091908 A1 AR091908 A1 AR 091908A1
Authority
AR
Argentina
Prior art keywords
benzene
preparation
methods
glucopiranos
ciclopropil
Prior art date
Application number
ARP130102660A
Other languages
English (en)
Inventor
Martin Hans
Juergen-Himmelsbach Frank
Butz Tanja
Eckhardt Matthias
Original Assignee
Boehringer Ingelheim Vetmed
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmed filed Critical Boehringer Ingelheim Vetmed
Publication of AR091908A1 publication Critical patent/AR091908A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un complejo cristalino de 1-ciano-2-(4-ciclopropil-bencil)-4-(b-D-glucopiranos-1-il)-benceno y uno o varios aminoácidos naturales, métodos para su preparación así como sus usos para preparar medicamentos.
ARP130102660A 2012-07-26 2013-07-25 COMPLEJO CRISTALINO DE 1-CIANO-2-(4-CICLOPROPIL-BENCIL)-4-(b-D-GLUCOPIRANOS-1-IL)-BENCENO, METODOS PARA SU PREPARACION Y SU USO PARA PREPARAR MEDICAMENTOS AR091908A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12177944 2012-07-26

Publications (1)

Publication Number Publication Date
AR091908A1 true AR091908A1 (es) 2015-03-11

Family

ID=48874313

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130102660A AR091908A1 (es) 2012-07-26 2013-07-25 COMPLEJO CRISTALINO DE 1-CIANO-2-(4-CICLOPROPIL-BENCIL)-4-(b-D-GLUCOPIRANOS-1-IL)-BENCENO, METODOS PARA SU PREPARACION Y SU USO PARA PREPARAR MEDICAMENTOS

Country Status (23)

Country Link
US (1) US9145434B2 (es)
EP (3) EP4166548A1 (es)
JP (2) JP6538556B2 (es)
CN (2) CN104470908A (es)
AR (1) AR091908A1 (es)
AU (1) AU2013294947B2 (es)
BR (1) BR112015001327B1 (es)
CA (1) CA2878698C (es)
DK (2) DK3351539T3 (es)
EA (2) EA201600506A1 (es)
ES (2) ES2694675T3 (es)
FI (1) FI3351539T3 (es)
HR (2) HRP20230081T1 (es)
HU (1) HUE061450T2 (es)
LT (1) LT3351539T (es)
MX (1) MX357906B (es)
PL (2) PL2877460T3 (es)
PT (2) PT3351539T (es)
RS (1) RS63881B1 (es)
SG (1) SG11201500574QA (es)
SI (2) SI2877460T1 (es)
TW (1) TW201418275A (es)
WO (1) WO2014016381A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9145434B2 (en) 2012-07-26 2015-09-29 Boehringer Ingelheim International Gmbh Crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ss-d-glucopyranos-1-yl)-benzene, methods for its preparation and the use thereof for preparing medicaments
FI2981269T3 (fi) 2013-04-04 2023-09-27 Boehringer Ingelheim Vetmedica Gmbh Aineenvaihduntahäiriöiden hoito hevoseläimillä
RS64990B1 (sr) 2013-12-17 2024-01-31 Boehringer Ingelheim Vetmedica Gmbh Sglt-2 inhibitor za primenu u lečenju metaboličkog poremećaja kod životinja iz roda mačaka
EA201891406A1 (ru) * 2014-01-23 2018-12-28 Бёрингер Ингельхайм Ветмедика Гмбх Лечение метаболических расстройств у представителей собачьих
NZ723781A (en) * 2014-04-01 2022-09-30 Boehringer Ingelheim Vetmedica Gmbh Treatment of metabolic disorders in equine animals
CN103965020B (zh) * 2014-05-06 2015-09-09 启东东岳药业有限公司 制备5-碘-2-溴苄醇的方法
US10555958B2 (en) 2014-09-25 2020-02-11 Boehringer Ingelheim Vetmedica Gmbh Combination treatment of SGLT2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals
CN105992769B (zh) * 2014-09-30 2019-04-02 江苏恒瑞医药股份有限公司 一种钠-葡萄糖协同转运蛋白2抑制剂的l-脯氨酸复合物、其一水合物及晶体
CZ2015110A3 (cs) * 2015-02-18 2016-08-31 Zentiva, K.S. Pevné formy empagliflozinu
ES2999279T3 (en) 2015-08-27 2025-02-25 Boehringer Ingelheim Vetmedica Gmbh Liquid pharmaceutical compositions comprising sglt-2 inhibitors
WO2017203457A1 (en) * 2016-05-26 2017-11-30 Dr. Reddy's Laboratories Limited Solid state forms of empagliflozin
JP6785523B2 (ja) * 2016-05-28 2020-11-18 ジ・リン・フイ・シェン・バイオ−ファーマシューティカル・カンパニー・リミテッドＪｉ Ｌｉｎ Ｈｕｉ Ｓｈｅｎｇ Ｂｉｏ−Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． ナトリウム−グルコース共輸送体２阻害剤の結晶形
MX2020006387A (es) * 2017-12-19 2020-09-03 Boehringer Ingelheim Vetmedica Gmbh Sintesis del cocristal 1:1:1 de 1-ciano-2-(4-ciclopropil-bencil)-4 -(beta-d-glucopiranos-1-il)-benceno, l-prolina y agua.
BR112022010385A2 (pt) 2019-11-28 2022-08-23 Boehringer Ingelheim Vetmedica Gmbh Uso de inibidores de sglt-2 na secagem de mamíferos não humanos
CN118615450A (zh) 2020-02-17 2024-09-10 勃林格殷格翰动物保健有限公司 Sglt-2抑制剂用于预防和/或治疗猫科动物的心脏疾病的用途
US20240307426A1 (en) 2021-07-28 2024-09-19 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of renal diseases in non-human mammals
CN117715640A (zh) 2021-07-28 2024-03-15 勃林格殷格翰动物保健有限公司 Sglt-2抑制剂用于在不包括猫科动物的非人哺乳动物，特别是犬科动物中预防和/或治疗心脏疾病的用途
EP4376819A1 (en) 2021-07-28 2024-06-05 Boehringer Ingelheim Vetmedica GmbH Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
TW202412756A (zh) 2022-05-25 2024-04-01 德商百靈佳殷格翰維美迪加股份有限公司 包含sglt-2抑制劑之水性醫藥組合物
WO2024184293A1 (en) 2023-03-06 2024-09-12 Boehringer Ingelheim Vetmedica Gmbh Systems for delivery of liquid pharmaceutical compositions in particular comprising one or more sglt-2 inhibitor(s)
CN121039113A (zh) 2023-04-24 2025-11-28 勃林格殷格翰动物保健有限公司 维格列净与所选共晶形成剂的结晶复合物、其制备方法及其在制备药物中的用途
WO2024240632A1 (en) 2023-05-24 2024-11-28 Boehringer Ingelheim Vetmedica Gmbh Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more sglt-2 inhibitors and pimobendan and/or telmisartan
AU2024277852A1 (en) 2023-05-24 2025-10-16 Boehringer Ingelheim Vetmedica Gmbh Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more sglt-2 inhibitors and telmisartan

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60209343T2 (de) 2001-04-11 2006-10-26 Bristol-Myers Squibb Co. Aminosäurekomplexe von c-arylglycosiden zur behandlung von diabetes und verfahren
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
JP2006516257A (ja) * 2003-01-03 2006-06-29 ブリストル−マイヤーズ　スクイブ　カンパニー Ｃ−アリールグルコシドｓｇｌｔ２阻害剤の製造法
CN103467423B (zh) * 2004-03-16 2016-03-16 贝林格尔.英格海姆国际有限公司 吡喃葡萄糖基取代的苯基衍生物、含该化合物的药物、其用途及其制造方法
WO2007028814A1 (en) * 2005-09-08 2007-03-15 Boehringer Ingelheim International Gmbh CRYSTALLINE FORMS OF 1-CHLORO-4-(ß-D-GLUCOPYRANOS-1-YL)-2-(4-ETHYNYL-BENZYL)-BENZENE, METHODS FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS
ATE517099T1 (de) 2006-02-15 2011-08-15 Boehringer Ingelheim Int Glucopyranosyl-substituierte benzonitril-derivate,pharmazeutische zusammensetzungen mit derartigen verbindungen, ihre verwendung und herstellungsverfahren dafür
TWI370818B (en) * 2006-04-05 2012-08-21 Astellas Pharma Inc Cocrystal of c-glycoside derivative and l-proline
PE20080697A1 (es) 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
TW200817424A (en) 2006-08-04 2008-04-16 Daiichi Sankyo Co Ltd Benzylphenyl glucopyranoside derivatives
PE20090185A1 (es) 2007-03-22 2009-02-28 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
US20080287529A1 (en) * 2007-05-18 2008-11-20 Bristol-Myers Squibb Company Crystal structures of sglt2 inhibitors and processes for preparing same
CN103319445B (zh) * 2007-12-27 2016-01-20 阿斯利康公司 Sglt2抑制剂的晶体结构及其制备方法
SMT201600475T1 (it) * 2008-08-22 2017-03-08 Theracos Sub Llc Procedimenti per la preparazione di inibitori di sglt2.
WO2010023594A1 (en) 2008-08-28 2010-03-04 Pfizer Inc. Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives
WO2010048358A2 (en) 2008-10-22 2010-04-29 Auspex Pharmaceutical, Inc. Ethoxyphenylmethyl inhibitors of sglt2
WO2011153712A1 (en) * 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
US9145434B2 (en) 2012-07-26 2015-09-29 Boehringer Ingelheim International Gmbh Crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ss-d-glucopyranos-1-yl)-benzene, methods for its preparation and the use thereof for preparing medicaments
FI2981269T3 (fi) 2013-04-04 2023-09-27 Boehringer Ingelheim Vetmedica Gmbh Aineenvaihduntahäiriöiden hoito hevoseläimillä

Also Published As

Publication number Publication date
JP6538556B2 (ja) 2019-07-03
EP2877460B1 (en) 2018-09-12
CN108774200A (zh) 2018-11-09
TW201418275A (zh) 2014-05-16
SI3351539T1 (sl) 2023-03-31
JP2015522644A (ja) 2015-08-06
MX2015000962A (es) 2015-04-16
LT3351539T (lt) 2023-02-10
EA025438B1 (ru) 2016-12-30
AU2013294947B2 (en) 2017-03-30
EP2877460A1 (en) 2015-06-03
EA201500038A1 (ru) 2015-07-30
PL2877460T3 (pl) 2019-04-30
EP4166548A1 (en) 2023-04-19
MX357906B (es) 2018-07-30
WO2014016381A1 (en) 2014-01-30
ES2937665T3 (es) 2023-03-30
DK2877460T3 (en) 2019-01-07
DK3351539T3 (da) 2023-01-30
US20140031540A1 (en) 2014-01-30
EP3351539B1 (en) 2022-11-09
EA201600506A1 (ru) 2017-03-31
EP3351539A1 (en) 2018-07-25
PT2877460T (pt) 2018-12-19
CA2878698A1 (en) 2014-01-30
US9145434B2 (en) 2015-09-29
ES2694675T3 (es) 2018-12-26
CN104470908A (zh) 2015-03-25
HRP20181972T1 (hr) 2019-01-25
RS63881B1 (sr) 2023-02-28
PT3351539T (pt) 2023-01-17
SI2877460T1 (sl) 2018-12-31
AU2013294947A1 (en) 2015-01-22
SG11201500574QA (en) 2015-02-27
BR112015001327B1 (pt) 2022-08-16
FI3351539T3 (fi) 2023-02-19
HRP20230081T1 (hr) 2023-03-17
JP2018135384A (ja) 2018-08-30
CA2878698C (en) 2021-03-23
BR112015001327A2 (pt) 2017-07-04
PL3351539T3 (pl) 2023-03-06
HUE061450T2 (hu) 2023-07-28

Similar Documents

Publication Publication Date Title
AR091908A1 (es) COMPLEJO CRISTALINO DE 1-CIANO-2-(4-CICLOPROPIL-BENCIL)-4-(b-D-GLUCOPIRANOS-1-IL)-BENCENO, METODOS PARA SU PREPARACION Y SU USO PARA PREPARAR MEDICAMENTOS
NI201400061A (es) Anticuerpos anti - phf - tau y sus usos
CL2014002903A1 (es) Composición geopolimérica de aluminosilicato; método de preparacion y sus usos.
UY34680A (es) Anticuerpos humanos anti-cd27, métodos, y usos
BR112015002091A2 (pt) método para a produção de um polipeptídeo, polipeptídeo, uso de um polipeptídeo e composição
LT2776469T (lt) Antikūno molekulės, pasižyminčios specifiškumu žmogaus ox40
DK3878495T3 (da) Engangsinjektionspen til flere anvendelser
DK3777840T3 (da) Rna-formulering til immunterapi
CO7121320A2 (es) Anticuerpos anti-hla-b*27 y usos de estos
PL3073959T3 (pl) Zespól szczepiący do podawania szczepionki do młodej kury
MX386584B (es) Composiciones de liberación retardada de linaclotida.
BR112012032008A2 (pt) anticorpos s100a4 e usos terapêuticos do mesmo
CO7091179A2 (es) Nuevos derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos
MX2015012833A (es) Composiciones antibioticas de ceftolozano.
BR112015022347A2 (pt) composição para vacinação, método para produzir uma composição para vacinação e uso de composição
MX379476B (es) Derivados de manosa, un proceso para su preparación y sus usos como un fármaco.
CL2013002581A1 (es) Compuestos derivados de indol-y -bencimidazol carboxamidas; pprocedimiento para prepararlos; uso de dichos còmpuestos para producir plaguicidas; y compuestos intermediarios.
ITMI20132052A1 (it) Impianto di alimentazione di carburante e procedimento per farlo funzionare.
CR20150257A (es) Derivados de n-(piridin-2-il)pirimidin-4-amina que contiene un grupo sulfoximina
CL2013003206A1 (es) Uso de compuestos derivados de metil y etil-carboxamidas de trifluorometil-benzotiofenos, en metodos para promover el crecimiento de plantas.
BR112014026564A2 (pt) formulação, uso de uma formulação, e, processo para a preparação de uma formulação
CO7151478A2 (es) Formulaciones estabilizadas que contienen anticuerpos anti-dll4
BR112016007062A2 (pt) variantes de protoxina-ii e métodos de uso
BR112014027808A2 (pt) sal polimórfico do sal de oxalato de 6-o-(4-dimetilaminoetoxi) cinaroil fumagilol e métodos de produção e utilização do mesmo
CO7121318A2 (es) Elementos reguladores de plantas y sus usos

Legal Events

Date Code Title Description
FB Suspension of granting procedure